
VC trio debuts seed fund; Takeda cuts early gene therapy work; Biogen’s new face of BD; Biotech investors get hands on; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
By now, most, if not all, of you will have heard about the exciting news that Endpoints has joined the Financial Times family. Thank you for all of your support over the years — and now, onto greater things!
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.